Summary
Signal counts
Assets tracked: 3
Watchlist assets: 3
Registry stop assets: 1
Sponsor overview
Jonsson Comprehensive Cancer Center
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT06067269 | https://clinicaltrials.gov/study/NCT03014804 | https://clinicaltrials.gov/study/NCT07229339 | https://clinicaltrials.gov/study/NCT03919071 | https://clinicaltrials.gov/study/NCT03191149 | https://clinicaltrials.gov/study/NCT06128070 | https://clinicaltrials.gov/study/NCT05538897 | https://clinicaltrials.gov/study/NCT07275216
Assets
Linked programs
- Apalutamide: Watchlist Signal (2/5)
- autologous dendritic cells pulsed with tumor lysate antigen Vaccine: Registry Stop Signal (4/5)
- Biospecimen Collection: Watchlist Signal (2/5)